CY2011011I1 - Υδατικα εναιωρηματα εστερων λιπαρων οξεων με 9-υδροξυρισπεριδονη - Google Patents

Υδατικα εναιωρηματα εστερων λιπαρων οξεων με 9-υδροξυρισπεριδονη

Info

Publication number: CY2011011I1
Authority: CY; Cyprus
Prior art keywords: hydroxyrisperidone; fatty acid; acid esters; aqueous suspensions; suspensions
Prior art date: 1996-05-20

Application number

CY2011011C

Other languages

English (en)

Other versions

CY2011011I2 (el

Original Assignee

Janssen Pharmaceutica N.V.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-20

Filing date

2011-08-18

Publication date

2016-12-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2011011(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-08-18 Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.

2016-12-14 Publication of CY2011011I2 publication Critical patent/CY2011011I2/el

2016-12-14 Publication of CY2011011I1 publication Critical patent/CY2011011I1/el

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

CY2011011C 1996-05-20 2011-08-18 Υδατικα εναιωρηματα εστερων λιπαρων οξεων με 9-υδροξυρισπεριδονη CY2011011I1 (el)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP96201429		1996-05-20
EP97923912A EP0904081B1 (en)	1996-05-20	1997-05-12	Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
PCT/EP1997/002504 WO1997044039A1 (en)	1996-05-20	1997-05-12	Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters

Publications (2)

Publication Number	Publication Date
CY2011011I2 CY2011011I2 (el)	2016-12-14
CY2011011I1 true CY2011011I1 (el)	2016-12-14

Family

ID=8224016

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CY0200021A CY2270B1 (en)	1996-05-20	2002-04-25	Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
CY2011011C CY2011011I1 (el)	1996-05-20	2011-08-18	Υδατικα εναιωρηματα εστερων λιπαρων οξεων με 9-υδροξυρισπεριδονη

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CY0200021A CY2270B1 (en)	1996-05-20	2002-04-25	Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters

Country Status (37)

Country	Link
US (1)	US6077843A (el)
EP (1)	EP0904081B1 (el)
JP (1)	JP3274687B2 (el)
KR (1)	KR100358373B1 (el)
CN (1)	CN1093762C (el)
AR (1)	AR007194A1 (el)
AT (1)	ATE208619T1 (el)
AU (1)	AU715572B2 (el)
BG (1)	BG62684B1 (el)
BR (1)	BR9706824B8 (el)
CA (1)	CA2236691C (el)
CY (2)	CY2270B1 (el)
CZ (1)	CZ291284B6 (el)
DE (2)	DE69708284T2 (el)
DK (1)	DK0904081T3 (el)
EA (1)	EA000536B1 (el)
EE (1)	EE03594B1 (el)
ES (1)	ES2167745T3 (el)
FR (1)	FR11C0035I2 (el)
HR (1)	HRP970276B1 (el)
HU (2)	HU224025B1 (el)
ID (1)	ID16927A (el)
IL (1)	IL124551A (el)
LU (1)	LU91842I2 (el)
MX (1)	MX9804816A (el)
MY (1)	MY126302A (el)
NO (2)	NO315931B1 (el)
NZ (1)	NZ330369A (el)
PL (1)	PL188309B1 (el)
PT (1)	PT904081E (el)
SI (1)	SI0904081T1 (el)
SK (1)	SK284013B6 (el)
TR (1)	TR199800923T2 (el)
TW (1)	TW487572B (el)
UA (1)	UA61898C2 (el)
WO (1)	WO1997044039A1 (el)
ZA (1)	ZA974331B (el)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA72189C2 (uk)	1997-11-17	2005-02-15	Янссен Фармацевтика Н.В.	Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
DE69917000T2 (de) *	1998-02-25	2005-04-21	Abbott Lab	Butorphanol enthaltende formulierungen mit verzögerter freisetzung
WO2000010572A1 (en) *	1998-08-18	2000-03-02	Sepracor Inc.	Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
BR0009437A (pt)	1999-03-31	2002-01-15	Janssen Pharmaceutica Nv	Amido pré-gelatinizado em uma formulação de liberação controlada
US6495164B1 (en) *	2000-05-25	2002-12-17	Alkermes Controlled Therapeutics, Inc. I	Preparation of injectable suspensions having improved injectability
CA2419314C (en) *	2000-08-14	2006-07-11	Teva Pharmaceutical Industries Ltd.	Preparation of risperidone
US7666445B2 (en) *	2000-10-20	2010-02-23	The Trustees Of The University Of Pennsylvania	Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
GB0216416D0 (en) *	2002-07-15	2002-08-21	Novartis Ag	Organic compounds
JP4500679B2 (ja) *	2002-07-29	2010-07-14	アルザ・コーポレーシヨン	パリペリドンを制御送達する方法および投薬形態物
US20050232995A1 (en)	2002-07-29	2005-10-20	Yam Nyomi V	Methods and dosage forms for controlled delivery of paliperidone and risperidone
GB0322994D0 (en) *	2003-10-01	2003-11-05	Novartis Ag	Organic compounds
AU2004285448C1 (en)	2003-10-23	2021-08-19	Otsuka Pharmaceutical Co., Ltd.	Controlled release sterile injectable aripiprazole formulation and method
US8221778B2 (en) *	2005-01-12	2012-07-17	The Trustees Of The University Of Pennsylvania	Drug-containing implants and methods of use thereof
US8329203B2 (en) *	2004-01-12	2012-12-11	The Trustees Of The University Of Pennsylvania	Drug-containing implants and methods of use thereof
CA2553254C (en) *	2004-01-12	2013-12-17	The Trustees Of The University Of Pennsylvania	Long-term delivery formulations and methods of use thereof
ES2245252B1 (es) *	2004-06-15	2007-03-01	Farmalider, S.A.	Solucion acuosa de risperidona para administracion oral.
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
EP1879890A1 (en)	2005-04-25	2008-01-23	Janssen Pharmaceutica N.V.	Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
PL116330U1 (en)	2005-10-31	2007-04-02	Alza Corp	Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
EP2359808B1 (en)	2006-08-09	2013-05-22	Intarcia Therapeutics, Inc	Osmotic delivery systems and piston assemblies
US8314110B2 (en) *	2007-04-19	2012-11-20	Youxin Li	Compounds for treating mental disorders, and preparation and uses thereof
CN104000779A (zh)	2007-04-23	2014-08-27	精达制药公司	促胰岛素释放肽的混悬制剂及其应用
US20090076035A1 (en) *	2007-09-15	2009-03-19	Protia, Llc	Deuterium-enriched paliperidone
SI2234617T2 (sl)	2007-12-19	2025-05-30	Janssen Pharmaceutica Nv	Režim odmerjanja v zvezi z dolgodelujočimi paliperidonijevimi estri za injiciranje
US20090209757A1 (en) *	2008-01-10	2009-08-20	Santiago Ini	Processes for the preparation and purification of paliperidone palmitate
CA2726861C (en)	2008-02-13	2014-05-27	Intarcia Therapeutics, Inc.	Devices, formulations, and methods for delivery of multiple beneficial agents
SI2341905T2 (sl)	2008-09-04	2024-02-29	Amylin Pharmaceuticals, Llc	Formulacije s podaljšanim sproščanjem z uporabo brezvodnih nosilcev
NO2462246T3 (el)	2009-09-28	2018-02-03
CA2742393A1 (en)	2009-10-30	2011-05-05	Janssen Pharmaceutica Nv	Dosing regimen associated with long-acting injectable paliperidone esters
WO2011074017A1 (en) *	2009-12-17	2011-06-23	Alkem Laboratories Ltd.	A novel process for the preparation of paliperidone
TWI577377B (zh)	2010-09-16	2017-04-11	Ｖｉｉｖ醫療保健公司	醫藥組合物
WO2012053654A1 (en)	2010-10-18	2012-04-26	Dainippon Sumitomo Pharma Co., Ltd.	Sustained-release formulation for injection
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2683717B1 (en) *	2011-05-31	2016-05-25	Ramamohan Rao, Davuluri	Preparation of 3-[2-[4-((6-fluoro-1, 2-benzisoxazol-3-yl)-l-piperidinyl)-6, 7, 8, 9-tetrahydro-9-hydroxy-2-methyl-4h-pyrido[ 1, 2-a]-pyrimidin-4-one (paliperidone) and paliperidone palmitate.
WO2013046225A2 (en) *	2011-08-10	2013-04-04	Glenmark Generics Limited	Process for the preparation of paliperidone palmitate
CN102993200B (zh) *	2011-09-10	2016-02-03	鲁翠涛	帕潘立酮氨基酸酯及其制备方法
EP3610890A1 (en)	2012-11-14	2020-02-19	The Johns Hopkins University	Methods and compositions for treating schizophrenia
US10525057B2 (en)	2013-09-24	2020-01-07	Otsuka Pharmaceutical Co., Ltd.	Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2802299T3 (es)	2015-04-07	2021-01-18	Janssen Pharmaceuticals Inc	Régimen de dosificación para dosis olvidadas para ésteres de paliperidona inyectables de acción prolongada
US10925639B2 (en)	2015-06-03	2021-02-23	Intarcia Therapeutics, Inc.	Implant placement and removal systems
TWI754643B (zh)	2016-05-16	2022-02-11	美商因塔希亞治療公司	升糖素受體選擇性多肽和彼之使用方法
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
WO2018129058A1 (en)	2017-01-03	2018-07-12	Intarcia Therapeutics, Inc.	Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
JP2023551007A (ja)	2020-11-30	2023-12-06	ヤンセンファーマシューティカエヌ．ベー．	パルミチン酸パリペリドン製剤の再懸濁を確実にする方法
DK4025188T3 (da)	2020-11-30	2024-03-04	Janssen Pharmaceutica Nv	Doseringsregimer associeret med injicerbare paliperidonformuleringer med forlænget frigivelse
EP4025189B1 (en)	2020-11-30	2024-06-05	Janssen Pharmaceutica NV	Dosing regimens associated with extended release paliperidone injectable formulations
EP4385564A3 (en)	2020-11-30	2024-10-09	JANSSEN Pharmaceutica NV	Dosing regimens associated with extended release paliperidone injectable formulations
HUP2100259A1 (hu)	2021-07-07	2023-01-28	Richter Gedeon Nyrt	Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
CA3229731A1 (en)	2021-08-20	2023-02-23	Janssen Pharmaceutica Nv	Dosing regimens associated with extended release paliperidone injectable formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5158952A (en) *	1988-11-07	1992-10-27	Janssen Pharmaceutica N.V.	3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) *	1988-11-07	1993-10-19	Janssen Pharmaceutica N.V.	3-piperidinyl-1,2-benzisoxazoles
CA2000786C (en) *	1988-11-07	1999-01-26	Cornelus G. M. Janssen	3-piperidinyl-1,2-benzisoxazoles
TW376319B (en) *	1993-04-28	1999-12-11	Janssen Pharmaceutica Nv	Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
HU219487B (hu) *	1993-11-19	2001-04-28	Janssen Pharmaceutica Nv.	Riszperidont tartalmazó mikrorészecskék, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények és előállításuk
US5650173A (en) *	1993-11-19	1997-07-22	Alkermes Controlled Therapeutics Inc. Ii	Preparation of biodegradable microparticles containing a biologically active agent
EP0729353B2 (en) *	1993-11-19	2012-09-12	Alkermes, Inc.	Preparation of biodegradable microparticles containing a biologically active agent
WO1996039405A1 (en) *	1995-06-06	1996-12-12	Hoechst Marion Roussel, Inc.	Pyridiniminyl-1,2-benzisoxazoles and- benzisothiazoles as antipsychotic agents
US5792477A (en) *	1996-05-07	1998-08-11	Alkermes Controlled Therapeutics, Inc. Ii	Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent

1997
- 1997-05-01 TW TW086105768A patent/TW487572B/zh not_active IP Right Cessation
- 1997-05-12 EA EA199800531A patent/EA000536B1/ru not_active IP Right Cessation
- 1997-05-12 TR TR1998/00923T patent/TR199800923T2/xx unknown
- 1997-05-12 EP EP97923912A patent/EP0904081B1/en not_active Expired - Lifetime
- 1997-05-12 DE DE69708284T patent/DE69708284T2/de not_active Expired - Lifetime
- 1997-05-12 IL IL12455197A patent/IL124551A/xx not_active IP Right Cessation
- 1997-05-12 NZ NZ330369A patent/NZ330369A/xx not_active IP Right Cessation
- 1997-05-12 AT AT97923912T patent/ATE208619T1/de active
- 1997-05-12 SI SI9730272T patent/SI0904081T1/xx unknown
- 1997-05-12 DE DE201112100027 patent/DE122011100027I1/de active Pending
- 1997-05-12 JP JP54150097A patent/JP3274687B2/ja not_active Expired - Lifetime
- 1997-05-12 DK DK97923912T patent/DK0904081T3/da active
- 1997-05-12 EE EE9800136A patent/EE03594B1/xx active Protection Beyond IP Right Term
- 1997-05-12 HU HU9901319A patent/HU224025B1/hu active Protection Beyond IP Right Term
- 1997-05-12 PL PL97327995A patent/PL188309B1/pl unknown
- 1997-05-12 PT PT97923912T patent/PT904081E/pt unknown
- 1997-05-12 CA CA002236691A patent/CA2236691C/en not_active Expired - Lifetime
- 1997-05-12 KR KR10-1998-0703629A patent/KR100358373B1/ko not_active Expired - Lifetime
- 1997-05-12 CZ CZ19981401A patent/CZ291284B6/cs not_active IP Right Cessation
- 1997-05-12 ES ES97923912T patent/ES2167745T3/es not_active Expired - Lifetime
- 1997-05-12 AU AU29559/97A patent/AU715572B2/en not_active Expired
- 1997-05-12 WO PCT/EP1997/002504 patent/WO1997044039A1/en not_active Ceased
- 1997-05-12 CN CN97191494A patent/CN1093762C/zh not_active Expired - Lifetime
- 1997-05-12 US US09/180,659 patent/US6077843A/en not_active Expired - Lifetime
- 1997-05-12 BR BRPI9706824-1B8A patent/BR9706824B8/pt not_active IP Right Cessation
- 1997-05-12 SK SK620-98A patent/SK284013B6/sk not_active IP Right Cessation
- 1997-05-19 ZA ZA974331A patent/ZA974331B/xx unknown
- 1997-05-19 ID IDP971649A patent/ID16927A/id unknown
- 1997-05-19 MY MYPI97002172A patent/MY126302A/en unknown
- 1997-05-19 AR ARP970102112A patent/AR007194A1/es active IP Right Grant
- 1997-05-20 HR HR970276A patent/HRP970276B1/xx not_active IP Right Cessation
- 1997-12-05 UA UA98052747A patent/UA61898C2/uk unknown
1998
- 1998-04-30 NO NO19981984A patent/NO315931B1/no not_active IP Right Cessation
- 1998-05-12 BG BG102443A patent/BG62684B1/bg unknown
- 1998-06-15 MX MX9804816A patent/MX9804816A/es unknown
2002
- 2002-04-25 CY CY0200021A patent/CY2270B1/xx unknown
2011
- 2011-07-20 LU LU91842C patent/LU91842I2/fr unknown
- 2011-08-18 HU HUS1100013C patent/HUS1100013I1/hu unknown
- 2011-08-18 CY CY2011011C patent/CY2011011I1/el unknown
- 2011-08-29 NO NO2011015C patent/NO2011015I2/no unknown
- 2011-09-02 FR FR11C0035C patent/FR11C0035I2/fr active Active

Also Published As

Publication number	Publication date
WO1997044039A1 (en)	1997-11-27
CN1206347A (zh)	1999-01-27
AR007194A1 (es)	1999-10-13
BR9706824B8 (pt)	2015-02-18
AU715572B2 (en)	2000-02-03
HUP9901319A3 (en)	1999-11-29
HUS1100013I1 (hu)	2017-03-28
TW487572B (en)	2002-05-21
ES2167745T3 (es)	2002-05-16
HRP970276A2 (en)	1998-04-30
DK0904081T3 (da)	2002-02-25
ATE208619T1 (de)	2001-11-15
KR100358373B1 (ko)	2003-02-11
NO315931B1 (no)	2003-11-17
SK284013B6 (sk)	2004-08-03
BG62684B1 (bg)	2000-05-31
ZA974331B (en)	1998-11-19
NO2011015I2 (no)	2013-03-11
HU224025B1 (hu)	2005-05-30
CY2270B1 (en)	2003-07-04
FR11C0035I1 (el)	2011-07-10
AU2955997A (en)	1997-12-09
EP0904081A1 (en)	1999-03-31
ID16927A (id)	1997-11-20
KR19990067603A (ko)	1999-08-25
EE03594B1 (et)	2002-02-15
SI0904081T1 (en)	2002-04-30
BG102443A (en)	1999-06-30
LU91842I2 (fr)	2011-09-20
EP0904081B1 (en)	2001-11-14
PL327995A1 (en)	1999-01-04
US6077843A (en)	2000-06-20
JP3274687B2 (ja)	2002-04-15
NO981984D0 (no)	1998-04-30
DE69708284T2 (de)	2002-07-25
MX9804816A (es)	1998-10-31
EE9800136A (et)	1998-10-15
MY126302A (en)	2006-09-29
CZ140198A3 (cs)	1999-04-14
UA61898C2 (en)	2003-12-15
DE69708284D1 (de)	2001-12-20
BR9706824A (pt)	1999-03-23
PT904081E (pt)	2002-04-29
JP2000513718A (ja)	2000-10-17
IL124551A0 (en)	1998-12-06
CZ291284B6 (cs)	2003-01-15
SK62098A3 (en)	2000-04-10
TR199800923T2 (xx)	1999-09-21
DE122011100027I1 (de)	2011-11-17
NO981984L (no)	1998-11-19
NZ330369A (en)	2000-04-28
NO2011015I1 (no)	2011-09-19
CA2236691A1 (en)	1997-11-27
EA000536B1 (ru)	1999-10-28
PL188309B1 (pl)	2005-01-31
FR11C0035I2 (fr)	2013-08-16
CA2236691C (en)	2007-01-02
CY2011011I2 (el)	2016-12-14
HRP970276B1 (en)	2002-04-30
HK1017852A1 (en)	1999-12-03
EA199800531A1 (ru)	1998-12-24
CN1093762C (zh)	2002-11-06
HUP9901319A2 (hu)	1999-08-30
IL124551A (en)	2001-08-26

Publication	Publication Date	Title
CY2011011I1 (el)	2016-12-14	Υδατικα εναιωρηματα εστερων λιπαρων οξεων με 9-υδροξυρισπεριδονη
DE69814451D1 (de)	2003-06-12	Wässrige suspensionen von submikron 9-hydroxyrisperidon fettsäureestern
FI950910A0 (fi)	1995-02-28	Rasvahappojohdannaiset
PT823895E (pt)	2004-11-30	Esteres de acidos gordos como composto bioactivos
BR9509004A (pt)	1998-06-02	Esteres alquiílicos do ácido fenilacético
DE59913680D1 (de)	2006-08-31	Fettsäurepartialester von Polyolen
DK0718275T3 (da)	1998-08-10	Kvaternære triethanolaminfedtsyreestere
DE69507006D1 (de)	1999-02-11	Ceramid-3-derivate von einfachungesättigten fettsäuren
DE50012694D1 (de)	2006-06-08	Verwendung von fettsäurealkanolaminestern
DE59803990D1 (de)	2002-06-06	Verwendung von fettsäurepolyglycolestersulfaten
DK142193D0 (da)	1993-12-21	Anvendelse af fedtsyreestere
DE69809692D1 (de)	2003-01-09	Herstellung von Carbonsäureestern
ATE221519T1 (de)	2002-08-15	Ester von 3-hydroxy-piperidinmethanol-derivaten
BR1100402A (pt)	2002-04-09	Derivados do ácido quinolona carboxìlico